APA (7th ed.) Citation

Ross, T., Kelly, K., Rinaldi, A., Lech, M., Martinez, R., Crowley, C., . . . Esler, W. (2019). PS-132-The acetyl-CoA carboxylase inhibitor PF-05221304 exerts direct effects on hepatic inflammation and fibrosis independent of benefits on steatosis. Journal of Hepatology, 70, e86. https://doi.org/10.1016/S0618-8278(19)30150-1

Chicago Style (17th ed.) Citation

Ross, Trenton, et al. "PS-132-The Acetyl-CoA Carboxylase Inhibitor PF-05221304 Exerts Direct Effects on Hepatic Inflammation and Fibrosis Independent of Benefits on Steatosis." Journal of Hepatology 70 (2019): e86. https://doi.org/10.1016/S0618-8278(19)30150-1.

MLA (9th ed.) Citation

Ross, Trenton, et al. "PS-132-The Acetyl-CoA Carboxylase Inhibitor PF-05221304 Exerts Direct Effects on Hepatic Inflammation and Fibrosis Independent of Benefits on Steatosis." Journal of Hepatology, vol. 70, 2019, p. e86, https://doi.org/10.1016/S0618-8278(19)30150-1.